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Brain metastasis is an ominous complication of can-
cer, yet most cancer cells that infiltrate the brain die
of unknown causes. Here, we identify plasmin from
the reactive brain stroma as a defense against meta-
static invasion, and plasminogen activator (PA)
inhibitory serpins in cancer cells as a shield against
this defense. Plasmin suppresses brain metastasis
in two ways: by converting membrane-bound astro-
cytic FasL into a paracrine death signal for cancer
cells, and by inactivating the axon pathfinding mole-
cule L1CAM, which metastatic cells express for
spreading along brain capillaries and for metastatic
outgrowth. Brain metastatic cells from lung cancer
and breast cancer express high levels of anti-PA ser-
pins, including neuroserpin and serpin B2, to prevent
plasmin generation and its metastasis-suppressive
effects. By protecting cancer cells fromdeath signals
and fostering vascular co-option, anti-PA serpins
provide a unifying mechanism for the initiation of
brain metastasis in lung and breast cancers.
INTRODUCTION
Metastasis is the main cause of death from cancer, but biologi-
cally, metastasis is a rather inefficient process. Most cancer cells
that leave a solid tumor perish, andmuch of this attrition happens
as circulating cancer cells infiltrate distant organs (Chambers
et al., 2002). Although mechanisms for early steps of tumor cell
dispersion and late stages of macrometastatic outgrowth are
known (Valastyan and Weinberg, 2011; Vanharanta and Mas-
sague´, 2013), the factors that determine the survival and adapta-1002 Cell 156, 1002–1016, February 27, 2014 ª2014 Elsevier Inc.tion of disseminated cancer cells in vital organs remain obscure.
Identifying these factors is particularly critical in the case of brain
metastasis. Brain relapse is the most devastating complication
of cancer, with acute neurologic distress and high mortality
being typical traits (Gavrilovic and Posner, 2005). The incidence
of brain metastasis is ten times higher than that of all primary
brain tumors combined (Maher et al., 2009). Lung cancer and
breast cancer are the top sources of brain metastasis, together
accounting for nearly two-thirds of total cases. However, it is
in the brain that infiltrating cancer cells face a particularly high
rate of attrition, as shown in experimental models (Kienast
et al., 2010). Brain metastasis tends to be a late complication
of cancer in the clinic (Feld et al., 1984; Karrison et al., 1999)
and is rare in mice with genetically engineered tumors that
readily metastasize to other organs (Francia et al., 2011;Winslow
et al., 2011).
The severe attrition of metastatic cells in the brain and the late
occurrence of brain metastasis in the clinic argue that circulating
cancer cells face major hurdles in colonizing this organ. Cancer
cells require specializedmechanisms to traverse the blood-brain
barrier (BBB), and molecular mediators of this process were
recently identified (Bos et al., 2009; Li et al., 2013). However,
most cancer cells that pass the BBB die (Heyn et al., 2006;
Kienast et al., 2010). Interestingly, cancer cells that succeed
in infiltrating the brain present the striking feature of adhering
to the surface of capillaries and growing as a sheath around
the vessels, whereas those that fail to co-opt the vasculature
also fail to thrive (Carbonell et al., 2009; Kienast et al., 2010;
Lorger and Felding-Habermann, 2010). What kills most cancer
cells that pass through the BBB, and what enables the few
survivors to co-opt the vasculature are questions of biologic
and clinical interest.
Seeking to define commonmechanisms for metastatic coloni-
zation of the brain, we focused on a small set of genes whose
expression is associated with brain metastatic phenotypes in
both lung and breast adenocarcinoma models. One of these
genes, SERPINI1, encoding the plasminogen activator (PA)
inhibitor neuroserpin (NS), is normally expressed mainly in the
brain. Tissue PA (tPA) and urokinase PA (uPA) convert plasmin-
ogen into plasmin, an endopeptidase thatmediates fibrinolysis in
blood clot resolution and is also involved in the stromal response
to brain injury (Benarroch, 2007; Sofroniew and Vinters, 2010).
Reactive astrocytes are major sources of PAs in ischemia and
neurodegenerative injury (Adhami et al., 2008; Ganesh and Chin-
tala, 2011; Teesalu et al., 2001). To avert the deleterious action of
plasmin, neurons express NS (Yepes et al., 2000). We found that
by secreting PA inhibitory serpins, brain metastatic cells thwart
the lethal action of plasmin from the reactive stroma. Moreover,
suppression of Fas-mediated cancer cell killing and promotion
of L1 cell adhesion molecule (L1CAM)-mediated vascular
co-option lie downstream of anti-PA serpin action as critical re-
quirements for the initiation of brain metastasis.
RESULTS
Association of PA-Inhibitory Serpins with the Brain
Metastatic Phenotype
To identify shared mediators of brain metastasis, we compared
the transcriptomic signatures of brainmetastatic subpopulations
(BrM) that were isolated from the lymph-node-derived human
lung adenocarcinoma cell lines H2030 and PC9 (Nguyen et al.,
2009) and the pleural-effusion-derived breast cancer cell lines
MDA-MB-231 (MDA231 for short) and CN34 (Bos et al., 2009;
Figure 1A). Seven genes were upregulated in brain metastatic
cells compared with the source parental lines in at least three
of the four models (Figure S1A available online). Among these
genes, LEF1 was previously defined as a mediator of WNT
signaling in brain metastasis (Nguyen et al., 2009). Of the
remaining genes, only SERPINI1, encoding NS, was associated
with brain relapse in human primary tumors (see below). This
was intriguing because NS expression is normally restricted
to neurons, where it protects against PA cytotoxicity (Yepes
et al., 2000).
The 36 serpin family members in human collectively target 18
proteases (Irving et al., 2000). Four serpins (NS and serpins B2,
E1, and E2) selectively inhibit PA (Law et al., 2006). The mRNA
levels for three of the four were upregulated >3-fold in brain met-
astatic cells (Figure 1A). Only one other serpin, SERPIND1, was
also upregulated (Figure 1A). Serpin D1 inhibits thrombin, which
cooperates with plasminogen in cerebral injury (Fujimoto et al.,
2008). Bone metastatic derivatives (MDA231-BoM) (Kang et al.,
2003) and lung metastatic derivatives (MDA231-LM2) (Minn
et al., 2005) were available for comparisons with MDA231-BrM2,
and showed little or no upregulation of the serpins (Figure 1B).
Additionally, we established the cell line ErbB2-P from a
mouse mammary tumor driven by a mutant ErbB2 transgene
(Muller et al., 1988) and then isolated a brain metastatic deriva-
tive (ErbB2-BrM2) by selection of ErbB2-P in congenic mice.
ErbB2-BrM2 cells showed a strong upregulation of serpins B2
and D1 compared with ErbB2-P (Figure 1A). We also screened
four cell lines derived from lymph nodemetastases of genetically
engineered KrasG12D;p53/ mouse lung adenocarcinomas
(Winslow et al., 2011). All four lines were highly metastaticto visceral organs but ranged widely in brain metastatic activity
(Figures 1C and S1B), and brain metastasis was associated
with high expression of serpins I1, B2, E2, and/or D1 (Figures
1C and 1D).
The upregulation of NS and serpin B2 in brain metastatic cells
was confirmed at the protein level (Figures S1C and S1D). More-
over, conditioned media from brain metastatic cells inhibited
the generation of plasmin activity from plasminogen (Figures
1E, 1F, and S1E). The only exception was PC9-BrM3, a cell
line that is less aggressive in brain metastasis compared with
H2030-BrM3 (Nguyen et al., 2009) and lacks upregulated anti-
PA serpins (Figures 1A, S1C, and S1D).
NS and Serpin B2 in Human Brain Metastasis Tissues
Focusing on the two most frequently upregulated anti-PA
serpins in these models, NS and serpin B2, we queried gene-
expression data from 106 primary lung adenocarcinomas with
relapse annotation (Nguyen et al., 2009). The expression level
of SERPINI1 and SERPINB2 in the tumors was associated with
brain relapse, both as individual genes (data not shown) and
combined (p = 0.018, hazard ratio = 2.33 ± 0.3; Figure 1G).
Expression of the two genes was not significantly associated
with metastasis to bone or lungs (p = 0.89, hazard ratio =
0.91 ± 0.33; p = 0.36, hazard ratio = 0.76 ± 0.27; Figures S1F
and S1G). SERPINI1 and SERPINB2 expression in breast tumors
was not a predictor of brain metastasis (p = 0.21, hazard ratio =
0.96 ± 0.16; Figure S1H), though in most of these cases brain
relapse was a late event that might have been seeded from
metastases in other organs.
We performed an immunohistochemical analysis of NS and
serpin B2 in human brain metastasis tissue using mouse brain
lesions formed by serpin-expressing human cancer cells as a
reference (Figure S1I). Among 33 metastases of non-small-cell
lung carcinomas (NSCLCs), 45% scored positive for NS and
94% scored positive for serpin B2. Among 123 metastases
from various subtypes of breast cancer, 77% scored positive
for NS and 34% scored positive for serpin B2 (Figures 1H, 1I,
S1I, and S1J). The immunoreactivity was distributed diffusely
in the cytoplasm of carcinoma cells and only minimally in the
scant extracellular stroma. Positivity for NS and serpin B2 in
the inflammatory infiltrate was limited.
Plasmin Is Lethal to Cancer Cells that Invade the Brain
Parenchyma
The MDA231-BrM2 and H2030-BrM3 models are metastatic to
the brain from orthotopic tumors and the arterial circulation
(Bos et al., 2009; Nguyen et al., 2009). We inoculated these cells
into the arterial circulation of immunodeficient mice via the left
cardiac ventricle and fixed the tissue to count cancer cells
lodged in the brain capillary network at different time points (Fig-
ures 2A–2C and S2A). One day after inoculation, we observed
isolated cancer cells trapped within brain capillaries (Figure 2B,
and H2030-BrM3 data not shown). Cells passing through the
BBB were observed between days 2 and 7 after inoculation (Fig-
ures 2B and S2B). All cells that remainedwithin capillaries on day
7 stained positive for the apoptosis marker, cleaved caspase-3
(Figures S2C and S2D). No intravascular cells were observed
thereafter. In parental MDA231, the number of extravasated cellsCell 156, 1002–1016, February 27, 2014 ª2014 Elsevier Inc. 1003
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Figure 1. Association of PA-Inhibitory Serpins with the Brain Metastatic Phenotype
(A) Serpin mRNA levels in brain metastatic cell lines relative to the levels in counterparts not metastatic to brain. TN, triple negative; ER, estrogen receptor
negative; PR, progesterone receptor negative.
(B) mRNA levels of the indicated serpins in the parental MDA231 cell line and derivatives with different metastatic tropisms. Error bars, 95% confidence interval.
(C) Representative ex vivo bioluminescence images of brains from syngeneic mice inoculated with KrasG12D;p53/mouse lung cancer cell lines. The percentage
of mice that developed brain metastasis and the mean BLI photon flux signal are indicated. n = 10.
(D) Heatmap of serpin mRNA expression in KrasG12D;p53/ derivatives.
(legend continued on next page)
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dropped sharply after day 5 and rarely recovered (Figure S2B). In
line with previous reports (Kienast et al., 2010; Lorger and Feld-
ing-Habermann, 2010), >90% of cancer cells that entered the
brain disappeared within days. In MDA231-BrM2, the number
of extravasated cells increased until day 7 and then dropped
sharply by day 10, but recovered by day 16. The survivors
were bound to and stretched over the abluminal surface of brain
capillaries (Figures 2A and 2B). Outgrowth occurred mainly on
co-opted vessels (Figure 2C; summarized in Figure 2D).
In the brain, metastatic cells were in close proximity to astro-
cytes (Figures 2E, S2E, and S2F), microglia, and neurons
(Figures S2G–S2J). Reactive astrocytes, identified by high glial
fibrillary acidic protein (GFAP) expression and a stellate
morphology, were associated with cancer cells right after extrav-
asation and thereafter (Figures 2E, S2E, and S2F). Reactive
astrocytes are a major source of PA in brain injury (Adhami
et al., 2008; Ganesh and Chintala, 2011). Indeed, mouse brain
sections harboring metastatic cells showed tPA and uPA immu-
noreactivity associated with astrocytes (Figures 2F and 2G).
Mouse astrocytes cultures were superior to microglia for con-
verting plasminogen to plasmin (Figure S2K). Neurons produce
plasminogen for neurite and synapse formation (Gutie´rrez-Fer-
na´ndez et al., 2009). Plasminogen immunoreactivity was associ-
ated with NeuN+ neurons near metastatic cells in mouse brain
(Figure 2H). Thus, the brain metastasis microenvironment con-
tains the necessary components for plasmin production.
To determine whether plasmin is harmful to metastatic cells in
the brain parenchyma, we used mouse brain slice cultures (Fig-
ure 2I). When placed on top of brain slices, H2030-BrM3 cells
migrated into the tissue, targeted blood capillaries, and spread
on the surface of the vessels (Figure 2J). H2030-BrM3 cells
proliferated under these conditions (Figures 2K and 2L), whereas
parental H2030 did not proliferate (Figures 2K and 2L) and under-
went apoptosis (Figures 2M and 2N). Similar results were ob-
tained with MDA231 cells (Figure S2N). In cocultures of cancer
cells with astrocytes and microglia, plasminogen addition trig-
gered apoptosis in parental H2030, but not in H2030-BrM3 (Fig-
ures S2L and S2M). The brain slices contained endogenous
plasmin activity, and addition of a plasmin inhibitor, a2-antiplas-
min (Bajou et al., 2008), inhibited this activity (Figures S2O and
S2P) and increased the survival of parental H2030 cells in the
slices (Figures 2K–2N). Of note, addition of plasmin to cancer
cell monolayer cultures did not trigger apoptosis (Figure S2Q).
These results suggested that plasmin acting through unknown
substrates kills infiltrating cancer cells in the brain, whereas
highly metastatic cells are shielded from this threat (Figure 2O).(E) Summary of the serpin-PA-plasmin cascade.
(F) Inhibition of plasminogen conversion into plasmin by cell culture supernatants
assay. Data are averages ± SEM from triplicate experiments.
(G) Kaplan-Meier analysis of brain-metastasis-free survival in 106 cases of lung a
the primary tumor. The p value was calculated from a Cox proportional hazardmo
(H) Representative human brain metastasis samples from lung and breast cance
(I) Proportion of metastasis samples that scored positive for NS immunostaining (r
of breast carcinoma. Small diagrams in the breast cancer set represent the prima
positive) of the serpin-positive samples for which this information was available. B
of the lung cancer and breast cancer cases, respectively. Samples scored as po
Scale bar, 100 mm. See also Figure S1.NS Protects Metastatic Cells from Plasmin-Mediated
Attrition
To investigate the role of NS in brain metastasis, we first used
the H2030-BrM3 model, in which only this serpin is upregulated
(refer to Figure 1A). Brain lesions formed by H2030-BrM3 cells
showed strong NS immunoreactivity (Figure S3A). Two small
hairpin RNAs (shRNAs) that decreased NS expression and
secretion by >85% (Figures S3B and S3C) did not affect the
growth of H2030-BrM3 cells in culture (Figure S3D) but
inhibited the metastatic activity of these cells, as shown by
bioluminescence imaging (BLI) of marker luciferase in vivo
(Figures 3A–3D), BLI ex vivo (Figure 3B), and marker GFP
expression in brain sections (Figure 3E). NS depletion in
H2030-BrM3 decreased the number and size of brain lesions
(Figures 3F and S3E), with a >90% overall reduction in brain
tumor burden (Figure 3G). The few macroscopic lesions that
developed were rich in NS (Figure S3F), suggesting escape
from the knockdown.
NS knockdown did not inhibit the entry of H2030-BrM3 cells
into the brain parenchyma (Figure S3G) or their ability to cross
an endothelial/astrocyte BBB-like barrier in vitro, whereas the
knockdown of ST6GalNaC5, a mediator of BBB extravasation,
did (Bos et al., 2009; Figures S3H and S3I). In brain slice assays,
NS knockdown in H2030-BrM3 cells decreased the number of
infiltrated cells (Figures 3H and 3I) and increased apoptosis (Fig-
ures 3H and 3J), whereas overexpression of NS in parental
H2030 and MDA231 cells had the opposite effects (Figures 3K
and 3L).
BrainMetastasisMediated by the PA Inhibitory Function
of NS
PC9-BrM3 can infiltrate the brain but are less aggressive than
H2030-BrM3 in colonizing it (Nguyen et al., 2009) and show no
upregulation of anti-PA serpins (refer to Figure 1A). PC9-BrM3
cells were stably transduced with vectors encoding the wild-
type NS or a mutant (NSDloop) that is devoid of PA inhibitory
function (Takehara et al., 2009; Figures S3J–S3M). Wild-type
NS significantly increased the brain metastatic activity of
PC9-BrM3, whereas the mutant did not (Figures 3M and 3N).
PC9-BrM3 cells are also metastatic to bone (Nguyen et al.,
2009), and NS overexpression did not markedly affect this
activity (Figures 3M and 3N). NSDloop was also ineffective at
protecting the parental H2030 and MDA231 cells from
apoptosis in brain tissue (Figures 3K and 3L). These results
suggest that NS mediates brain metastatic activity in cancer
cells by inhibiting PA.of the indicated cell lines. Plasmin activity was determined by a chromogenic
denocarcinoma classified based on SERPINB2 and SERPINI1 mRNA levels in
del, with SERPINB2 and SERPINI1 expression treated as a continuous variable.
r stained with antibodies against NS or serpin B2.
ed) or serpin B2 immunostaining (orange) in 33 cases of NSCLC and 123 cases
ry tumor subtype (HER2, HER2+; ER/PR, hormone-receptor positive; TP, triple
rain metastases that scored positive for both serpins comprised 42% and 34%
sitive had >80% of neoplastic cells showing positive reactivity.
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Figure 2. Vascular Co-Option, Outgrowth, and Escape from Stromal Plasmin Action
(A) Metastatic cell interactions with brain capillaries. MDA231-BrM2 cells (green) remain bound to brain capillaries (red) after completing extravasation.
(B) Confocal analysis of the extravasation steps showing a GFP+ MDA231-BrM2 cell.
(C) Cluster of extravasatedMDA231-BrM2 cells forming a sheath around a brain capillary. All extravasated cells initially grew in thismanner. Blue, nuclear staining.
(D) Schema representing the initial steps and interactions during metastatic colonization of the brain.
(E) Exposure of metastatic H2030-BrM3 cells to GFAP+ reactive astrocytes (arrowheads) in the brain parenchyma at different time points after inoculation of
cancer cells into the circulation. Day 3: red, collagen IV; white, GFAP; green, GFP+ cancer cells; blue, nuclear staining.
(F and G) tPA and uPA immunofluorescence staining (arrowheads) associated with GFAP+ astrocytes in a mouse brain harboring GFP+ H2030-BrM3 cells
(green).
(H) Plasminogen immunofluorescence staining (white, arrowheads) is associated with NeuN+ neuron bodies (red) near a cluster of GFP+ metastatic cells (green)
in a mouse brain. Blue, nuclei.
(I) Schema of brain slice organotypic cultures. Cancer cells placed on the surface of slices migrate into the tissue and seek microcapillaries.
(J) Representative image of a brain slice harboring infiltrated H2030-BrM3 cells that are still round (open arrowheads) or already spread over brain capillaries
(closed arrowheads).
(K) Representative confocal images of brain slice tissue infiltrated with the indicated cancer cells. a2-antiplasmin was added to the indicated cultures. Note the
lower density and disorganized aspect of parental cells compared with the stretched morphology of BrM3 cells or parental cells with a2-antiplasmin.
(L) Quantification of GFP+ cancer cells in the experiments of (K). The numbers of cells per field of view (FOV) are averages ± SEM, n = 6–10 brain slices, scoring at
least two fields per slice, in at least two independent experiments.
(legend continued on next page)
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Role of Anti-PA Serpins in Brain Metastatic Breast
Cancer Cells
Unlike the H2030-BrM3 cells, most other brain metastatic
models and a large proportion of human brain metastatic tissues
overexpressed not one but multiple anti-PA serpins (refer to
Figures 1A and 1I). In MDA231-BrM2, a triple knockdown of
the three upregulated serpins (B2, D1, and NS; Figures
S4A–S4C) inhibited the brain metastatic activity of the cells
more than did the knockdown of any individual serpin (Figures
4A, 4B, S4G, and S4H). The knockdown of serpin B2 (Figures
S4D and S4E) partially inhibited the brain metastatic activity of
MDA231-BrM2, and the lost activity could be rescued by en-
forced overexpression of NS (Figures 4A, 4B, and S4F). Clonal
cell lines isolated from the MDA231-BrM2 population showed
heterogeneity in the overexpression of anti-PA serpins.
Compared with the parental MDA231 population, we observed
upregulation of NS in nine out of ten clones, serpin B2 in five
out of ten, and serpin D1 in eight out of ten (Figures 4C and
S4I). As a trend, clones with high levels of the three serpins
were more metastatic to brain than were clones with lower levels
(Figures 4D andS4J). Cloneswith high levels of NS and serpin D1
lost brain metastatic activity when transduced with NS shRNA
(Figure 4E). In the ErbB2-BrM2 model, the knockdown of its
only upregulated anti-PA serpin, serpin B2 (refer to Figure 1A),
strongly decreased the brain metastatic activity in immunocom-
petent mice (Figures 4F–4H). In sum, the evidence indicated that
expression of one or more anti-PA serpins provides lung cancer
and breast cancer cells with a critical advantage in the formation
of brain metastases.
Metastatic Cells Face FasL in the Brain
We searched plasmin substrate databases (MEROPS and
CutDB) for proteins whose cleavage might affect brain metas-
tasis (Bajou et al., 2008; Chen and Strickland, 1997; Nayeem
et al., 1999; Pang et al., 2004). We focused first on FasL, a pro-
apoptotic cytokine. FasL is amembrane-anchored homotrimeric
protein that binds to Fas, a receptor that activates proapoptotic
caspases through the adaptor protein FADD (Ashkenazi and
Dixit, 1998). FasL is highly expressed in reactive astrocytes in
ischemia, brain trauma, Alzheimer’s disease, encephalomyelitis,
and multiple sclerosis (Choi and Benveniste, 2004). Astrocytes
are the main source of FasL against invading T cells in enceph-
alomyelitis (Wang et al., 2013). Plasmin cleaves FasL at
Arg144, releasing sFasL as a diffusible cell death signal (Bajou
et al., 2008; Fang et al., 2012). Therefore, we asked whether
anti-PA serpins shield cancer cells from the lethal action of
plasmin-mobilized sFasL (Figure 5A).
FasL immunoreactivity in brain sections harboring H2030-
BrM3 lesions was concentrated on reactive astrocytes (Figures
5B and S5A). Human and mouse astrocytes expressed FasL(M) Cleaved caspase-3 immunofluorescence staining in brain slices harboring th
(N) Quantification of cleaved caspase-3-positive cancer cells in the experimen
averages ± SEM.
(O) Schematic summary showing neurons and astrocytes as sources of plasmi
infiltrating cancer cells.
All p values by Student’s t test. Scale bars, 25 mm (A), 5 mm (B and C), 5 mm (da
metastasis) (D), 10 mm (F–H), 100 mm (K), and 5 mm (M). See also Figure S2.in culture (Figures 5C and S5B). Addition of plasminogen
decreased the level of cell-bound FasL in these cultures and
increased sFasL in the supernatants (Figures 5C, 5D, and
S5C–S5E). Addition of anti-PA serpins or antiplasmin decreased
the level of sFasL in mouse brain slices (Figure 5E). These results
showed that the PA-plasmin system can mobilize stromal FasL
in response to metastatic invasion of the brain.
H2030, PC9, MDA231, and CN34 expressed Fas, as did
their BrM derivatives (Figure S5F). Addition of sFasL caused
apoptosis in BrM cells in monolayer cultures (Figures S5G–
S5I) and in brain tissue (Figures 5F–5H), even in the presence
of a2-antiplasmin (Figure S5J). Conversely, addition of anti-
FasL blocking antibody protected parental H2030 cells against
apoptosis in brain tissue (Figures 5G–5I). Thus, brain metastatic
cells are susceptible to apoptosis if they are exposed to sFasL
in the brain parenchyma, and this occurs downstream of
plasmin.
NS Shields Brain Metastatic Cells from Fas-Mediated
Killing
To determine whether Fas signaling caused the death of cancer
cells that infiltrated the brain, we used a FADD truncation mutant
that lacks the death effector domain (FADD-DD construct) and
acts as a dominant-negative inhibitor of Fas signaling (Chin-
naiyan et al., 1996; Figure 5J). Transduction of FADD-DD in the
H2030-BrM3 cell line (Figure 5K) prevented the activation of cas-
pase 3 by sFasL (Figure 5L). The apoptosis that anti-PA serpin-
depleted BrM cells suffer in brain tissue (refer to Figures 3H–3J
and S5L) could be prevented by adding anti-FasL blocking anti-
bodies to the tissue cultures, as well as by enforcing the expres-
sion of FADD-DD in the cancer cells (Figures 5M, 5N, and S5L).
Moreover, FADD-DD partially rescued the metastatic activity of
NS-depleted H2030-BrM3 (Figure 5O). Collectively, these results
showed that anti-PA serpin activity shields metastatic cells from
FasL attack in the brain.
The Plasmin Target L1CAM Mediates Cancer Cell
Adhesion
Although inhibition of Fas signaling with FADD-DD protected
NS-depleted cancer cells from death in the brain, it did not fully
restore their metastatic activity (Figure 5O). The NS-depleted,
FADD-DD-expressing H2030-BrM3 cells formed smaller lesions
that were less well organized (Figure S6A). Therefore, we postu-
lated that anti-PA serpins promote brain metastasis by doing
more than just preventing FasL action.
Several clues led us to consider L1CAM as a relevant
mediator of metastasis in this context. L1CAM is mainly ex-
pressed in neural tissues and in tumors (Scha¨fer and Altevogt,
2010). It consists of six immunoglobulin-like (Ig) domains, five
fibronectin-like (FN) domains, a transmembrane region, ande indicated cells and additions.
ts of (M). Values are quantified as (L), normalized to H2030-BrM3, and are
nogen and PA, respectively, and the lethal effect of the resulting plasmin on
y 3), 15 mm (day 7), 25 mm (day 14), 70 mm (micrometastasis), 100 mm (macro-
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Figure 3. NS Mediates Brain Metastasis
(A) Schema of the experimental design.
(B) Representative images of whole-body BLI and brain ex vivo BLI 5 weeks after inoculation of H2030-BrM3 cells transduced with control shRNA or NS
shRNA (shNS).
(C) Kaplan-Meier plot of brain-metastasis-free survival in the experiment of (B). Control (n = 20) and two different shNS (shNS (1), n = 11; shNS (2), n = 13) were
analyzed; p values were obtained with the log rank Mantel-Cox test.
(D) Quantification of ex vivo BLI in brains from (B).
(legend continued on next page)
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Figure 4. Anti-PA Serpins Mediate Brain
Metastasis by Breast Cancer Cells
(A and B) MDA231-BrM2 cells transduced with
control vector; shRNA vectors targeting NS,
SERPINB2, and SERPIND1 (triple K/D); SERPINB2
shRNA (shSB2); or shSB2 plus an NS-expressing
vector were inoculated into the arterial circulation
of immunodeficient mice. Brain metastasis burden
was visualized by ex vivo brain BLI (A) and quan-
titated (B). Control n = 22, triple K/D n = 9, shSB2
n = 14, shSB2 and NS n = 8.
(C) Distribution of clones (single-cell progenies
[SCPs]) overexpressing one, two, or three of the
indicated serpins among ten clonal cell lines iso-
lated from the MDA231-BrM2 population.
(D) Ex vivo brain BLI quantification from different
MDA231-BrM2 SCPs injected. Red dots, SCP
(high levels of all serpins), n = 8; light green dots,
SCP (low levels of serpin B2), n = 11; blue dots,
SCP (low levels of serpin B2 and D1), n = 8; dark
green dots, SCP (low levels of serpin B2 and NS),
n = 5. The p value was determined by Student’s
t test.
(E) SCPs with high levels of NS and serpin D1 were
subjected to NS knockdown and tested for brain
metastatic activity.
(F) Kaplan-Meier survival curves for brain-metas-
tasis-free survival in syngeneic mice inoculated
with parental ErbB2-P cells (n = 9) or brain meta-
static derivatives ErbB2-BrM1 (n = 7) and ErbB2-
BrM2 (n = 5). Survival curves were compared using the log rank Mantel-Cox test. ErbB2-P versus ErbB2-BrM1, p = 0.0045; ErbB2-P versus ErbB2-BrM2,
p = 0.0053.
(G and H) Representative images (G) and quantification (H) of brain metastasis BLI photon flux formed by ErbB2-BrM2 or these cells expressing two different
serpin B2 shRNAs (shSB2). Control, n = 10; shSB2 (1), n = 10; shSB2 (2), n = 6.
Data are averages ± SEM. All p values were determined by Student’s t test, except in (F). See also Figure S4.an intracellular domain (Figure 6A). The L1CAM Ig-like repeats
mediate homo- and heterophilic interactions for axon guidance
(Maness and Schachner, 2007). L1CAM binds to itself, to integ-
rins (Felding-Habermann et al., 1997), and to other proteins
(Castellani et al., 2002; Donier et al., 2012; Kulahin et al.,
2008). L1CAM expression in tumors is implicated in invasion
(Voura et al., 2001) and associated with poor prognosis (Dober-
stein et al., 2011; Schro¨der et al., 2009). Plasmin cleaves
L1CAM at dibasic motifs (Lys860/Lys863), disrupting the
capacity for cell adhesion (Nayeem et al., 1999; Silletti et al.,
2000; Figure 6A).
Hence, we postulated that L1CAMmediates plasmin-sensitive
vascular co-option by metastatic cells in the brain. L1CAM(E) Representative images of coronal brain sections analyzed with immunofluores
into mice. Lesion contours are marked.
(F) Quantification of brain lesions according to size at the 21 day time point in (E).
number of lesions, p < 0.05.
(G) Quantification of brain tumor burden in the experiment of (E). Control n = 5, s
(H) Representative images of control and NS-depleted H2030-BrM3 cells in brai
(I and J) Quantification of GFP+ cells (I) and cleaved caspase-3 (J) in the experimen
slice, in at least two independent experiments.
(K and L) Quantification of cells that were positive for cleaved caspase-3, compa
(NSWT) or a mutant form unable to target PA (NSDloop) in parental cell lines H203
(M) Representative ex vivo BLI images of brains and hindlimbs from mice 21 da
(n = 5), NSWT (n = 7), or NSDloop mutant (n = 8).
(N) Ratio of photon flux in brain versus bone in the experiment of (M). Ex vivo bra
All p values were calculated by Student’s t test, except in (C). Scale bars, 250 mmwas expressed in the cancer cell lines regardless of their meta-
static activity, tumor type, or species of origin (Figures S6B
and S6C). H2030-BrM3 cells readily adhered to monolayers of
human brain microvascular endothelial cells (HBMECs; Figures
6B and 6C) and to monolayers of their own (Figure 6D). RNAi-
mediated knockdown of L1CAM (Figure S6B) inhibited these
cell-cell binding activities (Figures 6C and 6D). Addition of
plasmin to cancer cell monolayers caused a decrease in cell-
associated L1CAM levels, as shown by flow cytometry (Fig-
ure 6E) and by the accumulation of a 150 kDa fragment in the
media (Figure 6F; Mechtersheimer et al., 2001). Moreover,
plasmin-treated H2030-BrM3 cells lost cell adhesion capacity
(Figures 6G and 6H).cence (IF) against GFP at 21 or 35 days after inoculation of H2030-BrM3 cells
Control n = 5, shNS n = 6 brains; p value refers to size distribution. For the total
hNS n = 6.
n slice assays. Insets show cleaved caspase-3 IF.
t of (H). Data are averages ±SEM; n = 6–10 slices, scoring at least two fields per
ring parental and BrM cell lines, and the effect of overexpressing NS wild-type
0 (K) and MDA231 (L). Data are averages ± SEM, quantified as (J).
ys after inoculation with PC9-BrM3. Cells were transduced with empty vector
in mean BLI values are also shown.
(E), 100 mm, and 5 mm (inset) (H). See also Figure S3.
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Figure 5. NS Shields Cancer Cells from FasL Death Signals
(A) Schema of FasL and its conversion by plasmin into sFasL, a diffusible trigger of apoptosis through Fas-FADD signaling. TMD, transmembrane domain; SA,
trimeric self-assembly domain; THD, tumor necrosis factor-homology domain; red crosses, apoptotic cells; a, astrocyte; c, cancer cell.
(B) IF with antibodies against GFP (cancer cells), GFAP (reactive astrocytes), and FasL in amouse brain harboringmetastatic cells 21 days after arterial inoculation
of H2030-BrM3.
(C) Images of astrocyte cultures incubated with exogenous plasminogen (1 mM) or no additions. Staining was performed with antibodies against the extracellular
domain (ECD) or intracellular domain (ICD) of FasL.
(D) Western immunoblotting of supernatants from cultures shown in (C) using anti-FasL ECD antibodies.
(E) Mouse brain slices were incubated with a2-antiplasmin, NS, and serpin B2, or no additions. sFasL in tissue lysates was detected by western immunoblotting
with anti-FasL ECD. Quantification of band density relative to tubulin (left to right) yielded sFasL:FasL ratios of 1, 0.51, and 0.28.
(legend continued on next page)
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L1CAM Mediates Vascular Co-Option and Metastatic
Outgrowth
The molecular basis for vascular co-option in cancer remains
unknown. To address this issue, we asked whether L1CAM par-
ticipates in vascular co-option by metastatic cells in the brain.
L1CAM depletion in H2030-BrM3 cells did not affect their ability
to grow in culture (Figure S6D), infiltrate brain tissue, or seek cap-
illaries (Figures 6I and S6E). Notably, L1CAM depletion signifi-
cantly reduced the ability of H2030-BrM3 and MDA231-BrM2
cells to spread on the abluminal surface of the capillaries (Figures
6I, 6J, and S6G). This was accompanied with amarked decrease
in the proliferation marker Ki67 in vessel-associated cancer cells
(Figure 6K), without changes in apoptosis markers (Figure S6F).
PC9-BrM3 cells, which do not overexpress endogenous anti-
PA serpins, had a limited ability to spread on brain capillaries
(Figures 6L and 6M). Enforced expression of NS in these cells
not only augmented their metastatic activity (see Figure 3N)
but also increased their spreading on brain capillaries (Figures
6L and 6M) and their proliferation on the co-opted vessels
(Figure 6N). L1CAM depletion in PC9-BrM3-NS cells (Figures
S6H and S6I) abrogated these NS-dependent gains (Figures
6L–6N).
L1CAM Supports Metastasis Initiation Downstream of
NS
L1CAM immunostaining was clearly detectable on carcinoma
cells in amajority of the humanNSCLCbrainmetastasis samples
examined, and tended to be concentrated at cell interfaces
(Figures S7A and S7B). L1CAM-positive cells were present in
clusters. In the brain of inoculated mice, extravasated H2030-
BrM3 cells were spread over the basal lamina of capillaries,
without discernible contactswith the endothelial cells (Figure 7A).
L1CAM immunostaining in micrometastases was concentrated
at the interfaces of cancer cells with capillaries and adjacent
cancer cells (Figure 7B). In recently extravasated H2030-BrM3
cells, L1CAM-depletion allowed cell contact with capillaries
but prevented cell spreading over the capillaries (Figure 7C).
Twenty-one days later, L1CAM-depleted cells remained mostly
as single cells or small clusters, whereas the wild-type cells
readily expanded over the capillary network and formed large
colonies (Figures 7D and 7E). L1CAM knockdown markedly
decreased the overall brain metastatic activity of H2030-BrM3
and MDA231-BrM2 cells (Figures 7F–7H). Moreover, L1CAM(F) GFP+ H2030-BrM3 cells (green) were allowed to infiltrate brain slices in med
(red, inset).
(G and H) Quantification of total GFP+ cells (G) and apoptotic GFP+ cells (H) in the
n = 6–10 slices, scoring at least two fields per slice, from at least two independe
(I) GFP+ H2030 cells (green) were allowed to infiltrate brain slices in media c
endogenous signals from triggering caspase-3 activation (red, inset).
(J) Depiction of FADD-DD overexpression (yellow shape) to suppress proapopto
(K) FADD expression in H2030-BrM3 transduced with a FADD-DD vector.
(L) Quantification of apoptotic cells following sFasL addition to H2030-BrM3 cell
(M and N) Quantification of total GFP+ cells (M) and apoptotic GFP+ cells (N) in
additions. Data are averages ± SEM and quantitated as (G) and (H).
(O) Brain metastatic activity of H2030-BrM3 cells transduced with the indicated v
quantitated in cells transduced with control shRNA (n = 11), FADD-DD (n = 4), N
All p values were determined by Student’s t test. Scale bars, 25 mm (B), 200 mm
See also Figure S5.depletion abrogated the gain in metastatic activity of PC9-
BrM3 cells imparted by enforced NS overexpression (Figure 7I).
These results argued that L1CAM expression in metastatic cells
acts downstream of NS to mediate co-option of brain capillaries
and metastatic outgrowth.
DISCUSSION
The growing incidence of brain metastasis warrants a better
understanding of the molecular mechanisms that underlie this
condition. Our findings illuminate two critical requisites for met-
astatic colonization of the brain, namely, the escape of infiltrating
cancer cells from killing by reactive stromal signals, and the strik-
ing ability of the surviving cancer cells to co-opt brain capillaries
for metastatic expansion. We show that a stromal PA-plasmin
pathway and its inhibition by carcinoma serpins control both of
these processes in brain metastasis from lung and breast can-
cers, suggesting a unified mechanism for metastatic coloniza-
tion of the brain.
Anti-PA Serpins as Common Mediators of Brain
Metastasis
Brain metastasis involves close and sustained interactions of
cancer cells with brain capillaries and reactive astrocytes. Pre-
vious work (Carbonell et al., 2009; Kienast et al., 2010; Lorger
and Felding-Habermann, 2010) and our own studies show that
circulating cancer cells interact with capillary walls not only
during extravasation but also thereafter, by attaching to the
abluminal surface and growing as a sheath along the co-opted
vessels. Cancer cells that infiltrate the brain are immediately
exposed to astrocytes that abound in the perivascular space
and produce deleterious signals to repel invading cells. Cancer
cells must be shielded from such signals in order to survive
and to extract benefits from the stroma, including benefits
from astrocytes (Lin et al., 2010; Seike et al., 2011). We
show that the expression of anti-PA serpins in cancer cells pro-
vides such a shield. Serpin D1 and three out of four known
anti-PA serpins are expressed in our six brain metastasis
models. The most prominent of these serpins, NS and B2,
are expressed in a majority of brain metastases from lung can-
cer and breast cancer patients. The PA-plasmin system is well
characterized in connection with its role in blood clot resolu-
tion, but its role in cancer has remained paradoxical. Althoughia containing added sFasL or no additions and scored for cleaved caspase-3
experiments of (F) (orange bars) and (I) (green bars). Data are averages ± SEM,
nt experiments.
ontaining anti-FasL blocking antibody or no additions. Anti-FasL prevented
tic Fas signaling in cancer cells.
s transduced with the indicated vectors.
brain slices harboring the indicated GFP+ H2030-BrM3 transfectants and/or
ectors and inoculated into the arterial circulation of mice. BLI photon flux was
S shRNA (n = 14), or NS shRNA and FADD-DD (n = 12).
(C), 100 mm (F and I), and 5 mm (insets in F and I).
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Figure 6. The Plasmin Target L1CAM Mediates Vascular Co-Option by Brain Metastatic Cells
(A) Schema of L1CAM as a mediator of homophilic and heterophilic (e.g., integrins) cell adhesive interactions, and its conversion by plasmin into an adhesion-
defective fragment. Ig and fibronectin type III (FNIII) domain repeats, the ICD, and an integrin-binding RGD sequence are indicated.
(B) Suspensions of GFP+ H2030-BrM3 cells were placed on top of a monolayer of HBMECs.
(C and D) Analysis of H2030-BrM3 binding to HBMECmonolayers (C) or H2030-BrM3monolayers (D), and the effect of L1CAM knockdown. Data are averages ±
SEM, n = 5, scoring at least ten fields per coverslip.
(E) Flow cytometry of cell-surface L1CAM in the indicated brain cells expressing L1CAM shRNA or incubated with plasmin, compared with untreated controls.
(legend continued on next page)
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plasmin can promote cancer cell proliferation and invasion by
cleaving growth factor precursors and extracellular matrix pro-
teins (McMahon and Kwaan, 2008), anti-PA serpin levels in
tumors and blood are associated with poor outcome in many
cancers (Berger, 2002; Foekens et al., 1995; Harbeck et al.,
1999). Here we show that anti-PA serpins shield metastatic
cells from PA-plasmin in the brain, providing a clear prometa-
static advantage.
Averting Fas Killing and Protecting L1CAM Vascular
Co-Option
Although FasL plays important roles in immune homeostasis
(Krammer, 2000) and is present in tumors (Baldini et al., 2009),
its expression is particularly acute in reactive astrocytes (Beer
et al., 2000). Astrocytes are the main source of FasL in response
to infiltrating leukocytes, and of PAs in response to brain injury.
We show that metastasis-associated astrocytes express both
PA and FasL. Plasmin releases membrane-bound FasL from
astrocytes, and sFasL levels in brain tissue depend on plasmin.
Brain metastatic cells from lung or breast cancers suffer
Fas-dependent death in the brain unless they are protected by
anti-PA serpins. We conclude that Fas signaling mediates and
anti-PA serpins prevent the attrition of infiltrating cancer cells
in the brain.
We show that L1CAM mediates the spread of metastatic
cells on the vasculature and additionally mediates interactions
between cancer cells. When cancer cells are experimentally
depleted of L1CAM, they fail to co-opt brain capillaries and
metastatic outgrowth stalls. Cancer cell-derived anti-PA serpins
prevent plasmin destruction of L1CAM, providing yet another
benefit besides averting Fas-mediated cancer cell killing.
L1CAM expression is normally restricted to neurons, where it
mediates axonal guidance through highly plastic interactions of
the growth cone with surrounding components (Wiencken-
Barger et al., 2004). The dynamic nature of L1CAM adhesive
interactions might be particularly advantageous to cancer cells
in their quest to co-opt the vasculature while invading tissue.
Although the molecular basis for vascular co-option in cancer
is largely unknown, the present identification of L1CAM as a
mediator provides an opening for a mechanistic dissection of
this process.
Implications beyond Brain Metastasis
Themolecular mechanisms defined here protect metastatic cells
against selective pressures that are particularly acute in the
brain. However, a high mortality of infiltrating cancer cells is
characteristic of metastasis in general (Gupta and Massague´,
2006; Valastyan and Weinberg, 2011), and vascular co-option(F) Anti-L1CAM western immunoblotting of cells and culture supernatants after i
(G and H) Cancer cells were treated with plasmin and subjected to HBMEC adh
coverslip.
(I) Control or L1CAM-depleted H2030-BrM3 cells after infiltrating brain tissue slice
were visualized after 2 days. Two representative images are shown per conditio
(J and K) Quantification of cells that were spread on capillaries (J) and Ki67+ cells
least three fields per slice, from two independent experiments.
(L) Effect of NS overexpression and L1CAM depletion on the interaction of PC9-
(M and N) Quantification of cells that were spread on capillaries (M) and Ki67+ c
Data are averages ± SEM and quantitated as (J) and (K). All p values by Studentoccurs in metastasis to other organs and by other types of
cancer (Donnem et al., 2013). Vascular co-option also provides
cancer cells with an escape from therapy-induced hypoxia
(Leenders et al., 2004). The anti-PA serpins that are upregulated
in our brainmetastatic models are also expressed, albeit at lower
levels, in counterparts that are metastatic to other organs. More-
over, L1CAM expression in primary tumors is associated with
poor prognosis in various types of cancer, as are PA, plasmin,
and FasL. The reactive brain stroma, with its high capacity to
generate PA-plasmin and FasL, may bemore challenging to infil-
trating cancer cells than is the stroma in other organs, and as a
result, it may select for accentuated versions of otherwise gen-
eral metastatic traits. Although anti-PA serpins, plasmin, FasL,
and L1CAM have not previously been connected to metastatic
cell survival and vascular co-option, their repeated clinical asso-
ciation with poor prognosis and the mechanistic links exposed
in the present work may reflect a wider role in cancer than is
shown here.
EXPERIMENTAL PROCEDURES
Animal Studies
All animal experiments were done in accordance with a protocol approved
by the MSKCC Institutional Animal Care and Use Committee. Athymic NCR
nu/nu, Cr:NIH bg-nu-xid, FVB/NCr (all from NCI-Frederick), and B6129SF1/J
(The Jackson Laboratory) female mice 4–6 weeks of age were used. Brain
metastatic derivatives of a syngeneic ErbB2 model (ErbB2-BrM2) were estab-
lished according to a previous protocol (Bos et al., 2009; Nguyen et al., 2009)
and are detailed in the Extended Experimental Procedures. Brain colonization
assays were performed as follows: We injected 100 ml of PBS into the left
ventricle containing 50,000 cells (for long-term experiments) or 500,000 cells
(for short-term experiments) in the case of MDA231-BrM2a, CN34BrM-2c,
H2030-BrM3, and PC9-BrM3, and 100,000 cells in the case of 373N1,
393N1, 482N1, 2691N1, and ErbB2-BrM2. Brain colonization was analyzed
in vivo and ex vivo by BLI. Anesthetized mice (ketamine 100 mg/kg/xylazine
10 mg/kg) were injected retro-orbitally with D-Luciferin (150 mg/kg) and
imaged with an IVIS Spectrum Xenogen machine (Caliper Life Sciences).
Bioluminescence analysis was performed using Living Image software,
version 2.50.
Brain Slice Assays
Organotypic slice cultures from adult mouse brain were prepared by adapting
previously described methods (Polleux and Ghosh, 2002). Brains from 4- to 6-
week-old athymic NCR nu/numice were dissected in Hank’s balanced salt so-
lution (HBSS) supplementedwith HEPES (pH 7.4, 2.5mM), D-glucose (30mM),
CaCl2 (1 mM), MgSO4 (1 mM), NaHCO3 (4 mM), and embedded in low-melting
agarose (Lonza) preheated at 42C. The embeddedbrainswere cut into 250mm
slices using a vibratome (Leica). Brain slices (bregma 1 mm to +3 mm) were
placed with flat spatulas on top of 0.8 mm pore membranes (Millipore) in slice
culture media (Dulbecco’s modified Eagle’s medium [DMEM], supplemented
HBSS, fetal bovine serum 5%, L-glutamine (1 mM), 100 IU/ml penicillin,
100 mg/ml streptomycin). The brain slices were incubated at 37C and 5%ncubation with or without plasmin.
esion assays. Data are averages ± SEM, n = 3, scoring at least five fields per
s. GFP+ cancer cells (green) and vasculature (collagen IV immunostaining, red)
n. Bottom: high magnification.
(K) in the experiments of (I). Data are averages ± SEM, n = 6 slices, scoring at
BrM3 cells with capillaries in brain slices.
ells (N) in the experiments shown in (L).
’s t test. Scale bars, 10 mm (B) and 50 mm (I and L). See also Figure S6.
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Figure 7. L1CAM Mediates Metastatic
Outgrowth in the Brain
(A) GFP+ H2030-BrM3 co-opting the basal lamina
rich in collagen IV of endothelial cells labeled with
VE-cadherin in brain slices. bl, basal lamina; e,
endothelium; cc, cancer cell.
(B) Immunohistochemical staining with anti-
L1CAM antibodies and hematoxylin and eosin
(H&E) counterstaining of incipient brain colonies
formed by H2030-BrM3. Cancer cells (cc, pale
blue nuclei) remain close to each other and interact
with endothelial cells (e, dark blue nuclei). Insets:
higher magnification of cell-cell contact areas.
(C) H2030-BrM3 cells infiltrating the brain 7 days
after intracardiac injection, and the effect of
L1CAM depletion.
(D) Representative images of GFP+ metastatic
lesions from brains at 21 days.
(E) Relative abundance of macrometastasis
over micrometastasis (as defined in Figure 3F) in
brains shown in (D). Number of lesions: control =
283.2 ± 84.8, shL1CAM = 69.8 ± 11.5. Data are
averages ± SEM, n = 3 brains.
(F and G) Representative images (F) and quantifi-
cation (G) of ex vivo brain BLI frommice inoculated
with the indicated H2030-BrM3 cells. Control
shRNA, n = 9; shL1CAM, n = 6.
(H)Quantification of ex vivobrainBLI frommice that
were arterially inoculated with indicated MDA231-
BrM2cells.Control shRNA, n=9; shL1CAM, n = 10.
(I) Quantification of ex vivo brain BLI from mice
that were arterially inoculated with the indicated
PC9-BrM3 cells (n = 5–7). All p values were
determined by Student’s t test. Scale bar, 25 mm
(B), 30 mm (C), and 200 mm (D).
(J) Model of the action of the stromal PA-plasmin
system against cancer cells that infiltrate the
brain, and the role of anti-PA serpins in protecting
brain metastatic cells from stromal PA-plasmin.
Reactive astrocytes produce PAs in the presence
of extravasated cancer cells. Left side: metastasis
fails when PAs generate plasmin from neuron-
derived plasminogen and plasmin mobilizes FasL
from astrocytes to kill cancer cells. Additionally,
plasmin cleaves and inactivates L1CAM, a cell
adhesion molecule that cancer cells express for
vascular co-option. Right side: metastasis pro-
ceeds when brain metastatic cells express anti-
PA serpins that prevent the generation of plasmin
and its deleterious effects on the survival and
vascular attachment of the cancer cells.
See also Figure S7.CO2 for 1 hr, and then 33 10
4 cancer cells suspended in 2 ml of culture media
were placed on the surface of the slice and incubated for 48–72 hr. Brain slices
could be maintained under these conditions for up to 5 days without apparent
alterations in tissue architecture. a2-antiplasmin (2.5 mg/ml; Molecular Innova-
tions), NS, and serpin B2 (0.5 mg/ml each; Peprotech) were added to the me-
dium. sFasL (500 ng/ml; Peprotech) or FasL blocking antibodies (12.5 mg/ml;
BD) were added to the medium, and slices were preincubated for 24 hr before
addition of cancer cells. Brain sliceswere fixed in paraformaldehyde (4%) over-
night, and then free-floating immunofluorescence was performed for GFP
(1:1,000, ref. GFP-1020; Aves Labs), cleaved caspase-3 (1:500, ref. 9661;
Cell Signaling), collagen IV (1:500, ref. AB756P; Millipore). Nuclei were stained
with Bis-Benzamide (1 mg/ml; Sigma). Slices weremounted with ProLong Gold
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